Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Giesen, Nicola [VerfasserIn]   i
 Krämer, Isabelle [VerfasserIn]   i
 Schwarzbich, Mark-Alexander [VerfasserIn]   i
 Ho, Anthony Dick [VerfasserIn]   i
 Witzens-Harig, Mathias [VerfasserIn]   i
Titel:Analysis of clinical characteristics and outcome of patients with previously untreated diffuse large B-cell lymphoma and renal involvement in the rituximab era
Verf.angabe:Nicola Lehners, Isabelle Krämer, Mark-Alexander Schwarzbich, Anthony D. Ho & Mathias Witzens-Harig
E-Jahr:2016
Jahr:21 Mar 2016
Umfang:7 S.
Fussnoten:Gesehen am 18.06.2020
Titel Quelle:Enthalten in: Leukemia and lymphoma
Ort Quelle:London [u.a.] : Taylor & Francis Group, 1989
Jahr Quelle:2016
Band/Heft Quelle:57(2016), 11, Seite 2619-2625
ISSN Quelle:1029-2403
Abstract:Renal involvement in patients with lymphoma is rare but associated with poor prognosis. We analyzed characteristics and outcome of 22 patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) and renal involvement treated with a rituximab-containing regimen in curative intent. The majority of patients presented in advanced disease, 86% were Ann Arbor stage ≥ III and had an IPI score ≥ 3. Renal impairment was present in 32%. Outcome was poor with three-year progression-free survival (PFS) 44% and three-year overall survival (OS) 52% and significantly worse compared to DLBCL without renal involvement (p < 0.01). Patients with high-risk IPI had a significantly inferior prognosis compared to intermediate-risk IPI (three-year OS 0% vs. 75%, p = 0.01) as did those with renal impairment. A high rate of central nervous system (CNS) relapse (8/22) was observed. Intravenous high-dose methotrexate and intrathecal therapy showed a trend toward prolonged time to CNS relapse. Implementation of CNS prophylaxis might therefore be considered in these high-risk patients.
DOI:doi:10.3109/10428194.2016.1157869
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.3109/10428194.2016.1157869
 DOI: https://doi.org/10.3109/10428194.2016.1157869
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:chemotherapeutic approaches
 lymphoma and Hodgkin disease
 prognostication
K10plus-PPN:1701039729
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68588577   QR-Code
zum Seitenanfang